|
Jul 24
|
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
|
|
Jul 24
|
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
|
|
Jul 23
|
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
|
|
Jul 23
|
Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”
|
|
Jul 23
|
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
|
|
Jul 23
|
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
|
|
Jul 22
|
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
|
|
Jul 22
|
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
|
|
Jul 22
|
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
|
|
Jul 22
|
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
|
|
Jul 22
|
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
|
|
Jul 21
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
|
|
Jul 21
|
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
|
|
Jul 21
|
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
|
|
Jul 21
|
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer
|
|
Jul 1
|
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
|
|
Jul 1
|
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
|
|
Jun 30
|
Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?
|
|
Jun 30
|
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
|
|
Jun 30
|
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
|